Asthma: Pathogenesis and novel drugs for treatment

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Olin, J Tod ^a   Wechsler, Michael E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ANTIASTHMATIC AGENT; BECLOMETASONE; BENRALIZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHEMOKINE RECEPTOR ANTAGONIST; CICLESONIDE; CORTICOSTEROID; DUPILUMAB; FLUOCINONIDE; FLUTICASONE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INDACATEROL; LEBRIKIZUMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; MOMETASONE FUROATE; MONTELUKAST; MUSCARINIC RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RESLIZUMAB; SALMETEROL; TIOTROPIUM BROMIDE; TOLL LIKE RECEPTOR AGONIST; UNINDEXED DRUG; ANTIIDIOTYPIC ANTIBODY; ETHANOLAMINE DERIVATIVE; MONOCLONAL ANTIBODY;

ASTHMA; B LYMPHOCYTE; BASEMENT MEMBRANE; BRONCHIAL THERMOPLASTY; COST OF ILLNESS; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; ENDOSCOPIC THERAPY; EOSINOPHIL; GOBLET CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LOW DRUG DOSE; LYMPHOID CELL; MAST CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; RESPIRATORY EPITHELIUM; REVIEW; T LYMPHOCYTE; BRONCHUS; INHALATIONAL DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; PROCEDURES; PULSED RADIOFREQUENCY TREATMENT; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SMOOTH MUSCLE; SURGERY; TRENDS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BRONCHI; ETHANOLAMINES; HUMANS; MOLECULAR TARGETED THERAPY; MUSCLE, SMOOTH; PULSED RADIOFREQUENCY TREATMENT; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84913557801     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5517     Document Type: Review

References (171)

1. Masoli M, Fabian D, Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469-78.
2. WHO. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. www.who.int/gard/publications/GARD%20Book%202007.pdf.
3. Suissa S. Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortallty. J Allergy Clin Immunol 2001; 107:937-44.
4. Suissa S. Ernst R Benayoun S. Baltzan M. Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-6.
5. Eder W. Ege MJ. von Mutius E. The asthma epidemic. N Engl J Med 2006; 355:2226-35.
6. Pearce N. Aïtkhaled N. Beasley R. Mallol J, Keil U. Mitchell E; the ISAAC Phase Three Study Group. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12:315-35.
7. Akinbami LJ. Moorman JE. Bailey C. Zahran HS. King M. Johnson CA. et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief 2012:94:1-3.
8. Kausel L, Boneberger A, Calvo M., Radon K. Childhood asthma and allergies in urban, semiurban, and rural residential sectors in Chile. Scientific World Journal 2013:2013:937935.
9. Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001-2009. MMWR Morb Mortal Wkly Rep 2011; 60:547-52.
10. Von Mutius E., Martinez FD, Fritzsch C, Nicolai T Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am j Respir Crit Care Med 1994; 149:358-64.
11. Nicolai T, Carr D, Weiland S.K., Duhme H., von Ehrenstein O, Wagner C, et al. Urban traffic and pollutant exposure related to respiratory outcomes and atopy in a large sample of children. Eur Respir J 2003; 21:956-63.
12. Clark NA, Demers PA, Karr C.J., Koehoorn M., Lencar C, Tamburic L, et al. Effect of early life exposure to air pollution on development of childhood asthma. Environ Health Perspect 2010; 118:284-90.
13. Strachan DR Cook DG. Health effects of passive smoking. 6. Parental smoking and childhood asthma: longitudinal and case-control studies. Thorax 1998; 53:204-12.
14. Camargo CAJr, Weiss ST, Zhang S, Willett W.C., Speizer FE. Prospective study of body mass index, weight change, and riskof adult-onset asthma in women. Arch Intern Med 1999; 159:2582-8.
15. Ege MJ, Mayer M, Normand A.C., Genuneit J., Cookson WO, Braun-Fahrlander C, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011:364:701-9.
16. Custovic A, Rothers J, Stern D., Simpson A, Woodcock A, Wright AL, et al. Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies. J Allergy Clin Immunol 2011; 127:390-97 e1-9.
17. Erkkola M, Nwaru Bl, Kaila M, Kronberg-Kippila C, Honen J., Simell O, et al. Risk of asthma and allergic outcomes in the offspring in relation to maternal food consumption during pregnancy: a Finnish birth cohort study. Pediatr Allergy Immunol 2012; 23:186-94.
18. Nwaru Bl, Takkinen HM, Niemela O, Kaila M, Erkkola M, Ahonen S, et al. Timing of infant feeding in relation to childhood asthma and allergic diseases. J Allergy Clin Immunol 2013; 131:78-86.
19. Pearce N, Ait-Khaled N, Beasley R., Mallol J, Keil U, Mitchell E., et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62:758-66.
20. Sullivan PW. Ghushchyan VH. Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Suney. J Allergy Clin Immunol 2011; 127:363-69 e1-3.
21. Bonilla S, Kehl S, Kwong K.Y., Morphew T., Kachru R, Jones CA. School absenteeism in children with asthma in a Los Angeles inner city school. J Pediatr 2005; 147:802-6.
22. Silverstein MD, Mair JE, Katusic SK, Wollan PC, O'Connell EJ, Yunginger JW School attendance and school performance: a population-based study of children with asthma. J Pediatr 2001; 139:278-83.
23. Barnett SB, Nurmagambetov TA Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011; 127:145-52.
24. Chung KR Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-73.
25. Carolan BJ, Sutherland ER. Clinical phenotypes of chronicobstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131:627-34; quiz 35.
26. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Not Med 2012; 18:716-25.
27. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-13.
28. Fitzpatrick AM, Teague WG, Meyers D.A., Peters SR Li X, Li H, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011:127:382-89 e1-13.
29. Chang TS, Lemanske RF Jr, Mauger DT, Fitzpatrick AM, Sorkness CA, Szefler SJ, et al. Childhood asthma clusters and response to therapy in clinical trials. J Allergy Clin Immunol 2014:133:363-9
30. Duffy DL, Martin NG, Battistutta D, Hopper JL, Mathews JD. Genetics of asthma and hay fever in Australian Mms. Am Rev Respir Dis 1990; 142:1351-8.
31. Moffatt MF, Gut IG, Demenais F, Strachan DR Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363:1211-21.
32. Brand S, Kesper DA, Teich R, Kilic-Niebergall E, Pinkenburg O, Bothur E, et al. DNA methylation of TH1/TH2 cytokine genes affects sensitization and progress of experimental asthma. J Allergy Clin Immunol 2012; 129:1602-10e6.
33. Perera F, Tang WY, Herbstman J, Tang D., Levin L, Miller R, et al. Relation of DNA methylation of 5'-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. PLoS One 2009; 4:e4488.
34. Joubert BR, Haberg SE, Nilsen R.M., Wang X, Vollset SE, Murphy SK, et al. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ Health Perspect 2012; 120:1425-31.
35. Szabo SM, Levy AR, Gooch K.L., Bradt R Wijaya H, Mitchell I. Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr Respir Rev 2013; 13(suppl 2):S9-15.
36. Navarro S, Cossalter G, Chiavaroli C., Kanda A, Fleury S, Lazzari A., et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol 2011; 4:53-65.
37. Salazar F, Ghaemmaghami AM. Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells. Front Immunol 2013; 4:356.
38. LambrechtBN, Hammad H. The airway epithelium in asthma. Nat Med 2012; 18:684-92.
39. Kallal LE, Schaller MA, Lindell D.M., Lira SA, Lukacs NW. CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. Eurj Immunol 2010; 40:1042-52.
40. Pichavant M, Charbonnier AS, Tarants, Brichet A, Wallaert B, Pestel J, et al. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment, J Allergy Clin Immunol 2005; 115:771-8.
41. Lambrecht BN, Hammad H. Lung dendritic cells in respiratory viral infection and asthma: from protection to immunopathology. Annu Rev Immunol 2012; 30:243-70.
42. Hammad H, Lambrecht BN. Lung dendritic cell migration. Adv Immunol 2007; 93:265-78.
43. Otero K, Vecchi A, Hirsch E., Kearley J, Vermi W, Del Prete A, et al. Nonredundant role of CCRL2 in lung dendritic cell trafficking. Blood 2010; 116:2942-9.
44. Maazi H, Lam J, Lombardi V., Akbari O. Role of plasmacytoid dendritic cell subsets in allergic asthma. Allergy 2013; 68:695-701.
45. Robinson DS, Hamid Q, Ying S., Tsicopoulos A, Barkans J, Bentley A.M., et al. Predominant TH2-like bronchoalveolarT-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
46. Oh CK, Geba GR Molfino N. Investigationaltherapeuticstargetingthe IL-4/IL-13 / STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19:46-54.
47. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96:41-101.
48. Cosmi L, Liotta F, Maggi E., Romagnani S, Annunziato F. Th 17 cells: new playersin asthma pathogenesis. Allergy 2011; 66:989-98.
49. Wilson RH, Whitehead GS, Nakano H, Free M.E., Kolls JK, Cook DN. Allergic sensitization through the airway primesTh 17-dependent neutrophilia and airway hyperresponsiveness. Am j Respir Crit Care Med 2009; 180:720-30.
50. Lloyd CM, Saglani S. T cells in asthma: influences of genetics, environment, and T-cell plasticity. J AllergyClin Immunol 2013; 131:1267-74; quiz 75.
51. O'Hehir R.E., Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am j Respir Crit Care Med 2009; 180:936-47.
52. Bacharier LB, Jabara H, Geha RS. Molecular mechanisms of immunoglobulin Eregulation. Int Arch Allergy Immunol 1998; 115:257-69.
53. Saenz SA, Siracusa MC, Perrigoue JG, Spencer SR Urban JF Jr, Tocker JE, et al. IL 25 elicits a multipotent progenitor cell population that promotes T(H) 2 cytokine responses. Nature 2010; 464:1362-6.
54. Her E, Frazer J, Austen K.F., Owen WFJr. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest 1991; 88:1982-7.
55. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12:117-29.
56. Zimmermann N, McBride ML, YamadaY Hudson SA, Jones C, Cromie KD, et al. Siglec-F antibody ad ministration to mice selectively reduces blood and tissue eosinophils. Allergy 2008; 63:1156-63.
57. Nutku E, Aizawa H, Hudson SA Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003; 101:5014-20.
58. Kita H. Eosinophils: multifunctional and distinctive properties. Int Arch Allergy Immunol 2013; 161(suppl 2):3-9.
59. Hogan SR Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy R et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008; 38:709-50.
60. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eurj Pharmacol 2006; 533:327-40.
61. Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev 2011; 242:31-50.
62. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160:1532-9.
63. Kato T, Takeda X Nakada T, Sendo F Inhibition by dexamethasone of human neutrophil apoptosis in vitro. Nat Immun 1995; 14:198-208.
64. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154:4719-25.
65. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and ILS levels in airway secretions in acute severe asthma: clinical and biologic significance. Am J Respir Crit Care Med 2000; 161:1185-90.
66. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164:S28-38.
67. Wadsworth B, Yang J, Dorscheid D. IL-13, asthma, and glycosylation in airway epithelial repair. In: Chang C, ed. Carbohydrates - comprehensive studies on glycobiology and glycotechnology. InTech, 2012.
68. Jeffery PK, Wardlaw AJ, Nelson F.C., Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140:1745-53.
69. Montefort S, Roche WR, Holgate ST. Bronchial epithelial shedding in asthmatics and non-asthmatics. Respir Med 1993; 87(suppl B):9-ll.
70. Xiao C, Puddicombe SM, Fields, Haywood J, Broughton-Head V, Puxeddu I. et al. Defective epithelial barrier function in asthma, J Allergy Clin Immunol 2011; 128:549-56 e1-12.
71. Erjefalt JS, Persson CG. Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. Thorax 1997; 52:1010-2.
72. Holgate ST, Davies DE, Lackie P.M., Wilson SJ, Puddicombe SM, Lordan JL Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105:193-204.
73. Puddicombe SM, Polosa R, Richter A., Krishna MT, Howarth PH, Holgate ST, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. EASES J 2000; 14:1362-74.
74. Gizycki MJ, Adelroth E, Rogers A.V., O'Byrne PM, Jeffery PK. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol 1997; 16:664-73.
75. Bossley CJ, Fleming L, Gupta A., Regamey N, Frith J, Oates T., et al. Pediatric severeasthma is characterized byeosinophiliaand remodeling without T(H)2 cytokimes. J Allergy Clin Immunol 2012; 129:974-82 el3.
76. Sonnappa S, Bastardo CM, Saglani S, Bush A., Aurora R Relationship between past airway pathology and current lung function in preschool wheezers. Eur Respir J 2011; 38:1431-6.
77. Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000; 162:1778-82.
78. Grainge CL, Lau LC, Ward J.A., Dulay V., Lahiff G, Wilson S, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011; 364:2006-15.
79. Doeing DC, Solway J. Airway smooth muscle in the pathophysiology and treatment of asthma, J Appl Physiol (1985) 2013; 114:834-43.
80. Hirst SJ, Barnes PJ, Twort CH. PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Am J Physiol 1996; 270(3 Pt 1):L415-28.
81. Cohen R Rajah R, Rosenbloom J, Herrick DJ. IGFBP-3 mediatesTGF-betal-induced cell growth in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 278:1545-51.
82. Cohn L, Homer RJ, Marinov A, Rankin J., Bottomly K. Induction of airway mucus production by Thelper 2 (Th 2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 1997; 186:1737-47.
83. Lee JJ, McGarry MP, Farmer S.C., Denzler KL, Larson KA, Carrigan PE, et al Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma, J Exp Med 1997; 185:2143-56.
84. Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals.; Clin Invest 2006; 116:309-21.
85. Patel AC, Brett TJ, Holtzman MJ. The role of CLCA proteins in inflammatory airway disease. Annu Rev Physiol 2009; 71:425-49.
86. Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120(5 suppl):S94-138.
87. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. http://www.ginasthma.org/.
88. Lemanske RF Jr., Mauger DT, Sorkness C.A., Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975-85.
89. Joos S, Miksch A, Szecsenyi J., Wieseler B, Grouven U, Kaiser T., et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63:453-62.
90. Peters SR Kunselman SJ, Icitovic N, Moore W.C., Pascual R., Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363:1715-26.
91. Kerstjens HA, Engel M, Dahl R., Paggiaro R Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367:1198-207.
92. Normansell R, Walker S, Milan S.J., Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.
93. Burch J, Griffin S, McKenna C., Walker S, Paton J, Wright K., et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal Pharmacoeconomics 2012; 30:991-1004.
94. Cox PG, Miller J, Mitzner W Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24:659-63.
95. Cox G, Thomson NC, Rubin A.S., Niven RM, Corris PA, Siersted HC, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356:1327-37.
96. Wechsler ME, Laviolette M, Rubin A.S., Fiterman J., Lapae Silva JR, Shah PL, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013; 132:1295-302.
97. Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol 2011; 128:939-45.
98. Guilbert TW Morgan WJ, Zeiger RS, Mauger D.T., Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-97.
99. Warner SM, Knight DA. Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2008; 8:44-8.
100. Saglani S, Lui S, Ullmann N., Campbell GA, Sherburn RT, Mathie SA, et al IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132:676-85 el3.
101. Rabe KF, Vermeire PA, Soriano J.B., Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-7.
102. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmon Med 2006; 6:13.
103. Wenzel SE, Busse WW. Severe asthma: lessons from the severe asthma research program. J Allergy Clin Immunol 2007;119:14-21; quiz 22-3.
104. Serra-Batlles J., Plaza V, Morejon E., Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-6.
105. Bosley CM, Parry DT, Cochrane GM Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994; 7:504-9.
106. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge A.L., Williams P., Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904-12.
107. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-55.
108. Nelson HS, Weiss ST, Bleecker E.R., Yancey SW Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
109. Philip G, Hustad C, Noonan G., Malice MP, Ezekowitz A, Reiss TF, et al Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:691-6 e6.
110. Philip G, Hustad CM, Malice M.P., Noonan G., Ezekowitz A, Reiss TF, et al Analysis of behavior-related adverse experiences in clinical trials of montelukast J Allergy Clin Immunol 2009; 124:699-706 e8.
111. LaForce C, Korenblat P, Osborne P., Dong F, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr Med Res Opin 2009; 25:2353-9.
112. Pearlman DS, Greos L, LaForce C., Orevillo CJ, Owen R, Higgins M. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008; 101:90-5.
113. Woodcock A Bleecker ER, Lotvall J, O'Byrne PM, Bateman ED, Medley H, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest 2013; 144:1222-9.
114. Reber LL, Daubeuf F Plantinga M, De Cauwer L, Gerlo S, Waelput W, et al. A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol 2012; 188:3478-87.
115. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373:1905-17.
116. Zhang Y, Leung DY Goleva E. Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma J Allergy Clin Immunol 2014; 133:1744-52. el.
117. Lai CK, Ho AS, Chan C.H., Tang J., Leung JC, Lai KN. Interleukin-5 messenger RNA expression in peripheral blood CD4+ cells in asthma J Allergy Clin Immunol 1996; 97:1320-8.
118. Hamid Q, Azzawi M, Ying S., Moqbel R, Wardlaw AJ, Corrigan C.J., et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87:1541-6.
119. Ying S, Durham SR, Corrigan C.J., Hamid Q., Kay AB. Phenotype of cells expressing mRNA for TH 2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995; 12:477-87.
120. Sakuishi K, Oki S, Araki M., Porcelli SA, Miyake S, Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 2007; 179:3452-62.
121. Dubucquoi S, Desreumaux P, Janin A., Klein O, Goldman M, Tavernier J., et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994; 179:703-8.
122. Phillips C, Coward WR, Pritchard D.I., Hewitt CR. Basophils express a type 2 cytokine profile on exposure to proteases from helminths and house dust mites. J Leukoc Biol 2003; 73:165-71.
123. Sehmi R, Wood LJ, Watson R, Foley R., Hamid Q, O'Byrne PM, et al. Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation. J Clin Invest 1997; 100:2466-75.
124. Molfino NA, Gossage D, Kolbeck R., Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42:712-37.
125. Sitkauskiene B, Johansson AK, Sergejeva S, Lundin S., Sjostrand M, Lotvall J. Regulation of bone marrow and airway CD34+ eosinophils by interleukin-5. Am J Respir Cell Mol Biol 2004; 30:367-78.
126. Johansson AK, Sergejeva S, Sjostrand M., Lee JJ, Lotvall J. Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways. Eur J Immunol 2004; 34:3135-45.
127. Ochiai K, Kagami M, Matsumura R., Tomioka H. IL-5 but not interferon-gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression. Clin Exp Immunol 1997; 107:198-204.
128. Gauvreau GM, Ellis AK, Denburg JA. Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009; 39:1297-306.
129. Leckie MJ, ten Brinke A, Khan J, Diamant Z., O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
130. Flood-Page P., Swenson C, Faiferman I., Matthews J, Williams M, Brannick L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-71.
131. Haldar P, Brightling CE, Hargadon B, Gupta S., Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
132. Nair P, Pizzichini MM, Kjarsgaard M, Inman M.D., Efthimiadis A., Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-93.
133. Pavord ID, Korn S, Howarth P., Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-9.
134. Castro M, Mathur S, Hargreave F Boulet LP, Xie F Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-32.
135. Busse WW, Katial R, Gossage D., Sari S, Wang B, Kolbeck R., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237-44.e2.
136. Laviolette M, Gossage DL, Gauvreau G, Leigh R., Olivenstein R, Katial R, et al Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086-96.e5.
137. Fish SC, Donaldson DD, Goldman S.J., Williams CM, Kasaian MT IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 2005;174:7716-24.
138. Kroegel C, Julius P, Matthys H., Virchow JC Jr, Luttmann W Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 1996; 9:899-904.
139. Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003; 3:45-50.
140. Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G., Marsh DG, Lichtenstein LM, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995; 155:2688-94.
141. Burd PR, Thompson WC, Max E.E., Mills FC. Activated mast cells produce interleukin 13. J Exp Med 1995; 181:1373-80.
142. Schmid-Grendelmeier P., Altznauer F Fischer B, Bizer C, Straumann A, Menz G, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002; 169:1021-7.
143. Li H, Sim TC, Alam R. IL-13 released by and localized in human basophils. J Immunol 1996; 156:4833-8.
144. Mueller TD, Zhang JL, Sebald W Duschl A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta 2002; 1592:237-50.
145. Goebeler M, Schnarr B, Toksoy A., Kunz M, Brocker EB, Duschl A, et al. Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology 1997; 91:450-7.
146. Li-Weber M., Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol 2003; 3:534-43.
147. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111:677-90; quiz 91.
148. Borish LC, Nelson HS, Lanz M.J., Claussen L., Whitmore JB, Agosti JM, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816-23.
149. Borish LC, Nelson HS, Corren J, Bensch G., Busse WW, Whitmore JB, et al. Efficacy of soluble IL-4receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-70.
150. Corren J, Busse W Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181:788-96.
151. Wenzel S, Ford L, Pearlman D., Spector S, Sher L, Skobieranda F et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-66.
152. Corren J, Lemanske RF Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-98.
153. Morishima Y Ano S, Ishii Y, Ohtsuka S, Matsuyama M, Kawaguchi M, et al. Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma. Clin Dev Immunol 2013; 2013:609395.
154. Bullens DM, Truyen E, Coteur L., Dilissen E, Hellings PW, Dupont L.J., et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006; 7:135.
155. Agache I, Ciobanu C, Agache C., Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010; 104: 1131-7.
156. Molet S, Hamid Q, Davoine F Nutku E, Taha R, Page N, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108:430-8.
157. Busse WW, Holgate S, Kerwin E., Chon Y, Feng J, Lin J., et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188:1294-302.
158. Barnes PJ. New drugs for asthma. Semin Respir Crit Care Med 2012; 33:685-94.
159. Gauvreau GM, Boulet LP, Cockcroft D.W., Baatjes A., Cote J, Deschesnes F et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophi lic responses. Am J Respir Crit Care Med 2008; 177:952-8.
160. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H., Stryszak P, Soni P, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010; 35:564-70.
161. Beeh KM, Kanniess F, Wagner F Schilder C, Naudts I, Hammann-Haenni A, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013; 131:866-74.
162. Guntur VP, Reinero CR The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol 2012; 12:68-75.
163. Hanania NA, Wenzel S, Rosen K., Hsieh HJ, Mosesova S, Choy DF et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187: 804-11.
164. Perez-de-Llano LA, Carballada F Castro Anon O, Pizarro M, Golpe R, Baloira A, et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010; 35:1221-7.
165. Peters MC, Mekonnen ZK, Yuan S, Bhakta N.R., Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify T2-high and T2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133:388-94.
166. Israel E, Chinchilli VM, Ford J.G., Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-12.
167. Slager RE, Otulana BA, Hawkins G.A., Yen YP, Peters SP, Wenzel SE, et al IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist J Allergy Clin Immunol 2012; 130:516-22.e4.
168. Wechsler ME, Kunselman SJ, Chinchilli V.M., Bleecker E., Boushey HA, Calhoun WJ, et al. Effect of beta 2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374:1754-64.
169. Adamko DJ, Sykes BD, Rowe BH. The metabolomics of asthma: novel diagnostic potential. Chest 2012; 141:1295-302.
170. Shaw DE, Berry MA, Thomas M, Green R.H., Brightling CE, Wardlaw AJ, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231-7.
171. Green RH, Brightling CE, McKenna S, Hargadon B., Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.